Invests in and operates a diverse portfolio of businesses across health, happiness, wealth, and intelligent manufacturing sectors. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 0.2× for every dollar of annual revenue.
No analyst target is on record for this company.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades 46% below its peak. The market has trimmed its expectations for the company.
Our checks did not surface a specific strength to highlight here.
A loss of $3.4B against $25.2B in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.67. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.